摘要
目的观察重组人白细胞介素-2联合抗结核药物治疗初治菌阳肺结核的临床疗效。方法将100例初治菌阳肺结核患者随机分为两组,治疗组49例,对照组51例。对照组采用2HRZE/4HR标准化疗方案,治疗组在2HRZE/4HR标准化疗方案基础上加用重组人白细胞介素-2,疗程均为6个月。观察两组患者的临床疗效、痰菌转阴率及T淋巴细胞亚群的变化。结果治疗组的治疗总有效率和痰菌转阴率均显著高于对照组(P<0.05);治疗组CD4+、CD4+/CD8+均较对照组明显改善(P<0.05)。结论重组人白细胞介素-2辅助治疗初治菌阳肺结核可显著改善免疫状态,提高痰菌阴转率,提高疗效。
Objective To observe the clinical effect on interleukin 2 combined with regular antituberculosis treatment for new smear positive pulmonary tuberculosis. Methods 100 cases with new smear positive pulmonary tuberculosis were ran-domly divided into treatment group （49 cases） and control group （51 cases）. All patients were treated with regular antitubercu-losis treatment of 2HRZE/4HR （H： Isoniazid, R： Rifampicin, Z： Pyrazinamide, E： Ethambutol）, and treatment group were given interleukin 2 additionally. All the treatment courses were 6 months. The total clinical effect , the rate of sputum negative conversion and peripheral blood T-lymphocyte subsets were compared. Results The total effective rate and the rate of sputum negative conversion in the treatment group were significantly higher than those in the control group （P〈0.05）. There were signifi-cant differences on the level of CD4＋,CD4＋/CD8＋T-lymphocyte subsets between the two groups （P〈0.05）. Conclusion Inter-leukin 2 can significantly improve the immune status, increase the total effective rate and the rate of sputum negative conversion in the adjuvant treatment of pulmonary tuberculosis patients.
出处
《中国现代医药杂志》
2014年第11期38-40,共3页
Modern Medicine Journal of China
